GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Articles|March 27, 2020
Join Our Reader Reactor Panel
Author(s)Heidi Anne Duerr, MPH
Take our brief survey and become a member of the Psychiatric Times Reader Reactor Panel.
Advertisement
Calling All Psychiatrists!
Are you passionate about psychiatry? Make your voice heard and have your say about what appears in your publication-Psychiatric Times.
Sign up today for the Psychiatric Times Reader Reactor Panel by taking this brief survey.
Advertisement
Related to this article
Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.
Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Why Generic Antidepressant Cycling Falls Short: Early Augmentation and TD Risk
4
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
5